ArticleCancer discovery2021
A CRISPR/Cas9-Engineered
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.
0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 160 citations in OpenAlex.
- Article
- Reframing early gastric carcinogenesis through lineage, niche, and evolution.Cancer metastasis reviews · 2026Review
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- The Great Escape: the systems biology of endocrine resistance and lineage plasticity.Endocrine-related cancer · 2026Review
- Harnessing human tumor organoids for cancer modeling and precision therapy.Protein & cell · 2026Review
- Loss of Kmt2c/d promotes gastric cancer and confers vulnerability to mTORC1 and PD-1 inhibition.The Journal of clinical investigation · 2026Article
- Gastric Cancer Organoids: Mechanistic Insights, Drug Discovery, and Translational Advances in Precision Medicine.Journal of gastric cancer · 2026Review
- Inducing physiological polarity and performing gene editing using CRISPR-Cas9 in human trophoblast organoids.Nature protocols · 2026Review
- ARID1A loss drives gastric signet ring cell carcinoma by regulating mucin production and secretion.Nature communications · 2026Article
- Organoids: From Bench to Bedside Applications.MedComm · 2026Review
- Organoids in cancer therapy: translational applications and clinical promise.Molecular cancer · 2026Review
- Integrating Network Pharmacology and In Vitro 3D Cardiac Organoid Model Validation to Investigate the Action Mechanism of Shenfu Xiangshao Decoction on Heart Failure.Journal of cardiovascular pharmacology · 2026Article
- Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair Deficiencies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrated single-cell and spatial transcriptomics reveal the differentiation drivers of gastric epithelial lineage progression.Frontiers in immunology · 2026Article
- Clinical significance and functional characterization of RRN3 in gastric cancer: insights from pan-cancer analysis and experimental validation.Frontiers in oncology · 2026Article
- Listening to the Past, Shaping the Future: A Data-mining Based and Visual Analysis of Five Decades of Gastric Carcinogenesis Research.Biological procedures online · 2025Article
- Inner ear organoids: Recent progress and potential applications.Fundamental research · 2025Review
- Aberrant PJA2-CHRM3 signaling creates a therapeutic vulnerability in gastric tumor.British journal of cancer · 2025Article
- Phage therapy and its role in cancer treatment and control.Folia microbiologica · 2025Review
- Endocrine cancer organoids in basic and translational medical research.Science China. Life sciences · 2025Review
53 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
23 authors at 5 institutions in 1 country.
Yuan-Hung LoDepartment of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California.
Kevin S KolahiDepartment of Pathology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-6190-5597
Yuhong DuDepartment of Pharmacology and Chemical Biology and Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, Georgia.
Chiung-Ying ChangDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Andrey KrokhotinHoward Hughes Medical Institute, Stanford University School of Medicine, Stanford, California.
Ajay NairDepartment of Systems Biology, Columbia University, New York, New York.ORCID 0000-0003-4521-5614
Walter D SobbaDepartment of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-0754-2262
Kasper KarlssonDepartment of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California.
Sunny J JonesDepartment of Systems Biology, Columbia University, New York, New York.ORCID 0000-0002-0271-2963
Teri A LongacreDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Amanda T MahDepartment of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California.
Bahar TercanInstitute for Systems Biology, Seattle, Washington.
Alexandra SockellDivision of Oncology, Stanford University School of Medicine, Stanford, California.
Hang XuDivision of Oncology, Stanford University School of Medicine, Stanford, California.
Jose A SeoaneDivision of Oncology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-3856-9177
Jin ChenHoward Hughes Medical Institute, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California.
Ilya ShmulevichInstitute for Systems Biology, Seattle, Washington.
Jonathan S WeissmanHoward Hughes Medical Institute, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California.
Christina CurtisDivision of Oncology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-0166-3802
Andrea CalifanoDepartment of Systems Biology, Columbia University, New York, New York.ORCID 0000-0003-4742-3679
Haian FuDepartment of Pharmacology and Chemical Biology and Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, Georgia.
Gerald R CrabtreeDepartment of Pathology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-9685-7911
Calvin J KuoDepartment of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California. cjkuo@stanford.edu.
Stanford Medicine · USHoward Hughes Medical Institute · USColumbia University · USEmory University · USInstitute for Systems Biology · US
Funding
Stanford/UNC Biomimetic U19 Research CenterU19AI116484 · NIAID · STANFORD UNIVERSITY · PI AMIEVA, MANUEL R, KUO, CALVIN J · 2015 to 2025
$13.5MUCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona, Jack Roth · 2017 to 2026
$12.9MPredicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5MRegulation of actively proliferating and quiescent intestinal stem cellsU01DK085527 · NIDDK · STANFORD UNIVERSITY · PI KUO, CALVIN J · 2009 to 2023
$6.9MSystematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer MedicineU01CA217858 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2017 to 2021
$6.1MATP-Dependent Chromatin Remodeling in Human MalignancyR01CA163915 · NCI · STANFORD UNIVERSITY · PI Gerald R. Crabtree · 2012 to 2026
$5.4MOrganoid-based Discovery of Oncogenic Drivers and Treatment Resistance MechanismsU01CA217851 · NCI · STANFORD UNIVERSITY · PI CURTIS, CHRISTINA N, JI, HANLEE P · 2017 to 2021
$4.7MSystematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbationU01CA217875 · NCI · EMORY UNIVERSITY · PI FU, HAIAN · 2017 to 2021
$4.5MModeling KRAS-Dependent Synthetic Lethality in Human Colon OrganoidsU01CA199241 · NCI · STANFORD UNIVERSITY · PI KUO, CALVIN J, SHOKAT, KEVAN M. · 2016 to 2019
$4.3MPersonalized cancer models to discover and develop new therapeutic targets.U01CA217883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KEMP, CHRISTOPHER J · 2017 to 2021
$4.3MHigh-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0MInhibitors of the G protein GNAS which drives pancreatic tumorigenesisR01CA244550 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHOKAT, KEVAN M. · 2020 to 2024
$2.0MNCI NIH HHS K00 CA212433NCI NIH HHS R01 CA163915NCI NIH HHS R01 CA244550NCI NIH HHS R35 CA197745NCI NIH HHS U01 CA199241NCI NIH HHS U01 CA217851NCI NIH HHS U01 CA217858NCI NIH HHS U01 CA217875NCI NIH HHS U01 CA217883NCI NIH HHS U54 CA224081NIAID NIH HHS U19 AI116484NIDDK NIH HHS U01 DK085527NIGMS NIH HHS K99 GM134154NIGMS NIH HHS R00 GM134154NIH HHS S10 OD012351NIH HHS S10 OD021764
Abstract
Mutations in
Indexed as
Cell Transformation, NeoplasticCRISPR-Cas SystemsDNA-Binding ProteinsHumansModels, BiologicalMutationStomach NeoplasmsTranscription FactorsARID1A protein, humanDNA-Binding ProteinsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.